Formed last year to use particle technologies licensed from Nektar Therapeutics Inc. for respiratory drug development, start-up Pearl Therapeutics Inc. pulled in $15.5 million in its first venture-backed financing round. (BioWorld Today)

Formed last year to use particle technologies licensed from Nektar Therapeutics Inc. for respiratory drug development, start-up Pearl Therapeutics Inc. pulled in $15.5 million in its first venture-backed financing round. (BioWorld Today)

News of a delay in the start of pivotal trials of bremelanotide in erectile dysfunction - and the possibility that safety concerns could limit the drug's use in that indication - sent shares of Palatin Technologies Inc. plunging more than 60 percent. (BioWorld Today)

News of a delay in the start of pivotal trials of bremelanotide in erectile dysfunction - and the possibility that safety concerns could limit the drug's use in that indication - sent shares of Palatin Technologies Inc. plunging more than 60 percent. (BioWorld Today)